Despite its potential, targeting PRC1 in cancer therapy poses several challenges. One major issue is the complexity of the PRC1 complex and its interactions with other regulatory proteins. Additionally, the redundancy within the polycomb group proteins makes it difficult to achieve selective inhibition without affecting normal cellular functions. Understanding the context-specific roles of PRC1 in different cancers is essential for developing effective and safe therapeutic strategies.
